Sponsor:
Aminex Therapeutics, Inc.
Code:
NCT07287917
Conditions
Melanoma (Skin Cancer)
HER2-low Hormone Receptor Positive Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AMXT 1501 Dicaprate
DFMO
Fulvestrant
Capivasertib
Pembrolizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-25. This information was provided to ClinicalTrials.gov by Aminex Therapeutics, Inc. on 2025-12-17.